UK regulator approves GSK’s COVID antibody 'Xevudy' or 'Sotrovimab'
The UK regulator MHRA has approved the GSK’s drug for COVID-19 which is basically 'Xevudy' or 'Sotrovimab' which is a monoclonal antibody. The drug is expected to cut hospitalisation and death by 79 percent. Like Molnupiravir, the drug is approved for those with mild to moderate COVID-19, which is at high risk of developing a severe disease.
The UK regulator MHRA has approved the GSK’s drug for COVID-19 which is known as 'Xevudy' or 'Sotrovimab' which is a monoclonal antibody. The drug is expected to cut hospitalisation and death by 79 percent. Like Molnupiravir, the drug is approved for those with mild to moderate COVID-19, which is at high risk of developing severe disease.
This is the second monoclonal antibody drug, which is approved by the UK MHRA, after Roche's drug. Unlike Molnupiravir, the drug is given via injection for over 30 minutes.
Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
BJP spent more than ₹103 crore on Google Ads since May 2018, maximum expenditure on videos
Apr 27, 2024 11:39 AM
Lok Sabha Election Phase 2: Experts decode the key trends and issues in key battleground states
Apr 26, 2024 11:53 PM
2024 Lok Sabha Election | Which way the wind blows in the second phase
Apr 26, 2024 6:09 PM